ClinicalTrials.gg
WithdrawnNCT04044781Updated Jan 10, 2022

A Phase 1, Open-Label, PET Study of T2310 & BPN14770

A Phase 1 interventional study of BPN14770, T2310 in To Determine Brain Target Occupancy of BPN14770, sponsored by Tetra Discovery Partners. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-10.

Sponsored by Tetra Discovery Partners (part of Shionogi) · Phase 1, Interventional, and Diagnostic

Why this study was withdrawn
Change in Research Direction

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a sponsor initiated, single site, first-in-human study of an investigational imaging agent for quantifying the topographically specific concentrations of the phosphodiesterase enzyme Type 4D (PDE4D) with positron emission tomography (PET) using a selective radioligand, [11C]T2310. T2310 will be measured with imaging techniques to characterize plasma exposure levels versus regionally specific target engagement fractions for oral doses of BPN14770, an investigational new drug (IND) for modulating PDE4D. BPN14770 is under evaluation for the treatment of Fragile X syndrome and Alzheimer's disease.

02

Conditions studied

  • To Determine Brain Target Occupancy of BPN14770
03

In context

Lead sponsor

Tetra Discovery Partners is the lead sponsor of 9 studies on the registry; none are open to participants now.

First submitted before Tetra Discovery Partners became part of Shionogi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Willing and able to provide written .
    1. Subjectively healthy
    1. Between 18 and 75 years, inclusive, but preference will be given to subjects who are less than 55 years old.
    1. The subject weighs at least 45 kg and has a between 18.0 and 32 kg/m2.
    1. Subjects should be willing to observe the following requirements from Screening until 90 days after the final follow-up visit: Male subjects must be willing to inform female partners of their participation in the study and must agree to use adequate contraceptive methods (vasectomy performed at least 6 months prior to dosing BPN14770 or use at least one barrier method of birth control). Female subjects: Female subjects must be surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to dosing of BPN14770), at least two years , or willing to use one barrier plus a hormonal contraceptive method of contraception from initial screening until one month after taking the last dose of study drug

Exclusion criteria

Exclusion Criteria:

    1. Known history or evidence of a medical condition, disorder, or disease that, in the opinion of the investigator, would pose a risk to subject safety, proper completion of the procedures, or the integrity of the study.
    1. Clinical laboratory studies suggestive of a medically meaningful disease or condition that, in the opinion of the investigator, could pose a risk to subject safety, proper completion of the procedures, or the integrity of the study.
    1. to MRI based on the standard MRI screening questionnaire at CBIC. Contraindications include ferromagnetic foreign bodies (e.g., shrapnel, ferromagnetic sheet metal fragments in the orbital area), certain implanted medical devices (e.g., older aneurysm clips, cardiac pacemakers), or claustrophobia.
    1. Unexpected findings on screening MRI that are indicative of an occult brain disease, or will potentially compromise subject safety or the scientific integrity of the study data.
    1. Previous exposure to ionizing radiation for research purposes, such that, in combination with the exposure from this study, their exposure to research associated radiation will be >50 mSv/year for the previous year.
    1. Subjects who are atopic, or have a known to any component of the formulation of BPN14770 or to [11C]T2310 PET scan.
    1. History of substance dependence, or current use of drugs of abuse.
    1. History of regular weekly alcohol consumption >21 units for male subjects or >14units for female subjects or unable to abstain from alcohol from 24 hours prior to Screening visits and 24 hours prior to Period 2 Day (-1) until discharge at the end of Period 2.

      1. Female subjects who are pregnant or lactating. 10. Use of any prescription drugs within 14 days or 5 half-lives (whichever is longer) before the first dose of an product, unless in the opinion of the investigator (or delegate) and the Sponsor's Medical Monitor the medication will not interfere with the study procedures, the pharmacokinetics of either the radiopharmaceutical or the investigational drug product, or compromise subject safety. An example of potentially acceptable drug use might be beta blockers in eye drops for glaucoma.
    1. Use of any non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or 5 half-lives (whichever is longer) before the first dose of the study agents, unless in the opinion of the Investigator (or delegate) and the Sponsor's Medical Monitor the medication will not interfere with the study procedures, the pharmacokinetics of either the radiopharmaceutical or the investigational drug product, or compromise subject safety.
    1. Subjects who have received an investigational drug as part in another study within the last 30 days or 5 half-lives of the investigational drug for the previous study (whichever is longer).
    1. History of acquired immunodeficiency syndrome (AIDS).
    1. Poor peripheral venous access.
    1. Donation of ≥450 mL blood or loss of blood during surgery within 30 days prior to Day 1.
    1. Plasma donation >100 mL within 7 days prior to Day 1.
    1. In the Investigator's judgement it is better for the subject not to be enrolled in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Test Group

    Stage 1 safety assessments will be performed before and after the administration of a single, 185 MBq (5mCi) dose of T2310 in up to three healthy volunteers. Stage 2 will evaluate the relationship between plasma concentration of BPN14770, an investigational PDE4D modulator, and brain target occupancy in up to six healthy volunteers.

    Drug: BPN14770, T2310

Interventions

  • Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.

06

What researchers measure

Primary outcomes

  1. Adverse Events

    To assess the safety and tolerability of \[11C\]T2310 when administered alone and when co-administered with BPN14770

    Time frame: 1-8 Days

  2. Plasma Concentration

    To determine relationships between plasma concentrations of BPN14770 and the total volume of distribution of T2310 as a proxy for brain PDE4D occupancy by BPN14770 following single oral dosing regimens of BPN14770 over a 24 hour time

    Time frame: 24 Hours

07

Study locations

1 site
  • Weill Cornell Medicine
    New York, New York 10065, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Apr 2020, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2019
First posted
Aug 5, 2019
StartActual
Jan 10, 2020
Primary completionActual
Apr 30, 2020
CompletionActual
May 30, 2020
Last update
Jan 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04044781
Responsible party
Sponsor
First posted
Aug 5, 2019
Start date
Jan 10, 2020
Primary completion
Apr 30, 2020
Completion
May 30, 2020
Last update
Jan 10, 2022

Study contacts

Paul D Mozley, MD
principal investigator · Weill Cornell College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BPN14770

Start the discussion